• news.cision.com/
  • Dicot Pharma AB/
  • Major shareholders, board members, and senior executives have committed to exercise TO4 warrants in Dicot, corresponding to 3.9 million SEK
English

Major shareholders, board members, and senior executives have committed to exercise TO4 warrants in Dicot, corresponding to 3.9 million SEK

Report this content

Press release: Uppsala, Sweden, May 31, 2023. Dicot AB (publ) ("Dicot") hereby announces that major shareholders of Dicot and all members of the board and management holding subscription warrants of series TO4 have committed to Dicot to exercise all of their warrants. This corresponds to a total investment of approximately SEK 3.9 million, representing approximately 16 percent of the total number of outstanding series TO4 subscription warrants. The subscription period runs from June 1 up to and including June 15, 2023.

"Once again, we see strong support from our largest owners, board and management. This confidence means a lot to us before the subscription period starts tomorrow", says Elin Trampe, CEO.

About the warrants of series TO4
If all warrants of series TO4 are exercised for the subscription of new shares, Dicot will receive approximately SEK 24.8 million before issuing costs. The last day of trading with the TO4 subscription warrants is June 13, 2023. For the warrants not to expire without value, it is required that the holder actively subscribes for shares no later than June 15, 2023, or sells the warrants no later than June 13, 2023. Please note that certain nominees may close their subscriptions earlier than June 15, 2023.

A summary of the terms:

  • Subscription period: June 1 – 15, 2023
  • Last day of trading in warrants of series TO4: June 13, 2023
  • Issue volume: 225,229,530 warrants of series TO4, which entitles to subscription of 225,229,530 shares. If all warrants are exercised, Dicot will receive approximately SEK 24.8 million before issuing costs.
  • Exercise price: SEK 0.11 per share.
  • Dilution: Upon full exercise of the warrants of series TO4, the number of shares may increase with not more than 225,229,530 shares, from 437,409,060 to 662,638,590 and the share capital to increase with not more than SEK 1,576,606.71, from SEK 3,061,863.42 to SEK 4,638,470.13. The increase in the share capital is calculated based on Dicot's share capital after reduction of the share capital which was resolved upon at the annual general meeting on May 23, 2023. If the warrants are fully exercised, the dilution amounts to approximately 34 % of the number of shares and votes in Dicot.

Please note that the warrants not used for subscription of new shares no later than June 15, 2023, or not sold no later than June 13, 2023, will expire without value. In order for the warrants not to lose their value, active subscription of shares or sale of warrants are required.

How the warrants are exercised

  • Nominee-registered warrants (Custody account):
    Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
  • Direct-registered warrants (Securities account):
    Prefilled application form will be sent out. Subscriptions will be made through simultaneous cash payment in accordance with the instructions on the application form.

The application form including instructions for payment will be available at Dicots’s webpage, www.dicot.se, and at Hagberg & Aneborn Fondkommision AB:s webpage www.hagberganeborn.se.

Advisors

Corpura Fondkommission AB (www.corpura.se) act as financial advisor and Advokatfirman Lindahl KB is legal adviser to the Company in connection to the warrants. Hagberg & Aneborn Fondkomission AB acts as issuing agent.

For further information, please contact:

Elin Trampe, CEO

Phone: +46 739 80 14 08

E-mail: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,100 shareholders. For more information, please visit www.dicot.se.

Subscribe

Documents & Links